The Gruppo Oncologico Nord Ovest (GONO) conducted a phase III study comparing fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI [irinotecan 165 mg/m 2 day 1, oxaliplatin 85 mg/m 2 day 1, leucovorin 200 mg/m 2 day 1, fluorouracil 3,200 mg/m 2 48-hour continuous infusion starting on day 1, every 2 weeks]) with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI).
INTRODUCTION
Colorectal carcinoma (CRC) is the second cause of cancer-related death in developed countries. 1 The combinations of irinotecan (CPT-11) ϩ fluorouracil (FU)/leucovorin (LV) and oxaliplatin (LOHP) ϩ FU/LV have demonstrated increased efficacy compared with FU/LV alone in randomized studies. [2] [3] [4] [5] [6] These data have established that in metastatic colorectal cancer, a more active firstline treatment can be also more effective in terms of improved progression-free survival (PFS) and overall survival (OS). 7 A study by the Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) 8 suggested that the exposure of metastatic colorectal cancer patients to all the three most active agents, irrespective of their sequence, is associated with promising survival. Moreover, a pooled analysis of seven phase III trials demonstrated that survival is correlated with the proportion of patients who received all the three active drugs in the course of their disease, but not with the proportion of patients who received any second-line therapy.
9 This analysis also shows that, in a sequential strategy, not all patients who progress after first-line chemotherapy are able to receive second-line treatment (50% to 80%) and, therefore, can be exposed to the three active agents.
A way to further improve the outcome of metastatic colorectal cancer patients could be to administer a first-line regimen containing the three active agents (LOHP, CPT-11 and FU/LV). This regimen, if feasible, could expose all patients to these drugs. If this regimen will be more active than a standard two-drug combination, it could also increase the postchemotherapy resection rate of metastases and, therefore, the long-term control of disease. In fact, studies conducted with LOHP-and FU-based regimens 10, 11 and, more recently, also with different combinations, 12 indicate that an active first-line chemotherapy in initially unresectable patients can allow a radical resection of metastatic disease and 20% to 40% of these resected patients are long-term survivors. In particular, an analysis conducted by Folpercht et al 13 demonstrates a correlation between the response rate to chemotherapy and the postchemotherapy radical resection rate of metastases.
Therefore, we studied the feasibility and the activity of a triplet combination containing FU/LV, LOHP, and CPT-11. In an initial phase I-II study 14 a chronomodulated infusion of FU was used, and in a subsequent phase II study, a simplified FU/LV, LOHP, and CPT-11 (FOLFOXIRI) regimen was developed. 15 Treatment was well tolerated, response rate was 72%, with a median PFS of 10.8 months and median OS of 28.4 months. The combined analysis of the two abovementioned studies demonstrated that in 26% of initially unresectable patients, a radical resection of residual metastatic disease could be performed. The 4-year survival of these patients was 37%. 16 On the basis of these results, the Gruppo Oncologico Nord Ovest (GONO) launched a phase III randomized trial to compare the simplified FOLFOXIRI regimen to a standard combination of FU/LV and CPT-11 (FOLFIRI) that had demonstrated improved efficacy in comparison to FU/LV.
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METHODS
Patient Selection
From , platelet count of at least 100,000/mm 3 , serum creatinine of 1.3 mg/dL or less, serum bilirubin less than 1.5 mg/dL and AST, ALT, and alkaline phosphatase 2.5 ϫ normal values or less (Յ 5 if liver metastases). Previous fluoropyrimidine-based adjuvant chemotherapy was allowed if ended more than 6 months before random assignment. Exclusion criteria were previous palliative chemotherapy for metastatic disease; previous chemotherapy including irinotecan or oxaliplatin, symptomatic cardiac disease, myocardial infarction in the last 24 months or uncontrolled arrhythmia, active infections, inflammatory bowel disease; and total colectomy. The study was conducted in accordance to Helsinki declaration and to Good Clinical Practice guidelines, and patients were informed of the investigational nature of the study and provided their written informed consent before registration onto the study. The protocol was approved by the ethics committee of all participating institutions.
Stratification, Random Assignment, and Treatment
Patients were stratified according to center, ECOG performance status (0 v 1 to 2) and history of adjuvant therapy (yes v no) and then were randomly assigned to FOLFIRI (arm A) or FOLFOXIRI (arm B; Fig 1) . Treatment was administered every 2 weeks until evidence of progression, unacceptable toxicity, patient refusal, or for a maximum of 12 cycles. Adverse events were evaluated according to National Cancer Institute Common Toxicity Criteria version 2.0. No prophylactic treatment for neutropenia was recommended.
Evaluation Criteria
Responses were evaluated every 8 weeks according to WHO criteria. The determination of responses and progression was initially based on investigator-reported measurements; computed tomography scans of all responding patients and of patients with stable disease were subsequently subjected to external review by an independent panel. Quality of life was assessed at the beginning of each treatment cycle using the Quality of Life Questionnaire of the European Organisation for Research and Treatment of Cancer (version 2.0).
Statistical Analysis
The primary study end point was the externally reviewed response rate (RR). Secondary end points were PFS, OS, postchemotherapy R0 surgical resections, safety, and quality of life. We selected RR as the primary end point because three meta-analyses of randomized studies in metastatic colorectal 
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cancer had demonstrated a clear correlation between RR and OS and between the RR and the rate of radical secondary surgery on metastases, supporting the use of RR as a surrogate end point. PFS was defined as the length of time from random assignment to disease progression or to death resulting from any cause, whichever occurred first, or to last contact. The evaluation of PFS was based on investigators' assessment. OS was defined as the length of time from random assignment to death or to last contact.
Assuming an RR of 40% in the FOLFIRI arm, to demonstrate an improvement of 20% in with FOLFOXIRI (60%), using a two-sided 2 test with a power of 0.80 and an alpha-error of 0.05, and considering approximately 10% of patients nonassessable, we planned to randomly assign a total of 240 patients. With this sample size, and assuming that we would observe the same results reported by Douillard 3 with FOLFIRI in terms of PFS, the study was also able to demonstrate, after 218 events had occurred, by two-tailed log-rank test (alpha-error ϭ 0.05, power 0.80), a prolongation in PFS of 3.1 months (from 6.7 to 9.8 months). For primary and secondary objectives we analyzed the intention-to-treat population, using 2 tests (or Fisher's exact test, if indicated) to compare categoric variables between treatment groups. We estimated survival curves by the Kaplan-Meier method, and compared the groups by the log-rank test. We tested the 14 following variables as possible predictive factors for objective response or surgical R0 resection and as possible prognostic factors: treatment, sex, age (Ͻ or Ն 65 years), WHO performance status (0 or 1 to 2), primary tumor site (colon or rectum), number of organs involved (single or multiple), sites of disease (liver only or other sites), liver involvement (Ͻ or Ն 25%), time from first diagnosis to first metastasis (0 to 3, 3 to 12, or Ͼ 12 months), previous adjuvant therapy (yes or no), baseline lactate dehydrogenase (normal or Ն upper limit of normal), baseline carcinoembryonic antigen (Ͻ or Ն 100 ng/mL), baseline leukocytes (Ͻ or Ն 8,000/mL), and baseline hemoglobin (Ͻ or Ն 10 g/dL). All multivariate analyses used a step-down procedure based on the likelihood ratio test. Multivariate analyses were done on the intention-to-treat population. A logistic-regression model was used to identify the predictive factors for objective response and surgical R0 resection. For time to progression and OS, Cox's proportional hazards modeling was used. The QLQ-C30 questionnaire was analyzed with the global health status/quality-of-life scale as the primary end point and the other 10 scales as secondary end points. Statistical analysis was performed using SPSS/ PCϩ11.5 statistical software (SPSS Inc, Chicago, IL).
RESULTS
Patients
A total of 244 patients from 15 Italian centers were enrolled onto the study and randomly assigned to FOLFIRI (n ϭ 122) or FOLFOXIRI (n ϭ 122). Table 1 presents the characteristics of the patients, which were balanced among the treatment groups. Overall, the study population was relatively selected to exclude elderly and frail patients with an expected increased risk of toxicity by using combination chemotherapy.
Treatment Administration and Safety
All randomly assigned patients received at least one cycle of study treatment and were evaluated for safety. Both treatments were relatively well tolerated and associated with manageable toxicities. As presented in Table 2 , the median number of administered cycles was 10 in the FOLFIRI arm and 11 in the FOLFOXIRI arm. The relative dose-intensity of administered FU, CPT-11, and LOHP ranged between 82% and 87% of planned for all agents in both arms. Treatment interruptions because of toxicity were 4% for FOLFIRI and 9% for FOLFOXIRI (P ϭ .19). No toxic deaths occurred, and two patients (1.6%) in each arm died within 60 days from the treatment start, all because of rapidly progressive disease. Most commonly observed toxicities were neutropenia, diarrhea, nausea/vomiting, stomatitis, peripheral neurotoxicity, alopecia, and thrombocytopenia (Table 3) . Grade 3 to 4 toxicities, however, were uncommon except for neutropenia. In particular, the adverse events that occurred significantly more often in patients who received FOLFOXIRI were grade 2 to 3 peripheral neurotoxicity (0% v 19%; P Ͻ .0001) and grade 3 to 4 neutropenia (28% v 50%; P ϭ .0006). Nevertheless, the incidence of febrile neutropenia was comparable between FOLFIRI and FOLFOXIRI (3% v 5% of patients; P ϭ .75), and there were no episodes of documented infections; granulocyte colony-stimulating factor was used in 2% of FOLFIRI cycles and in 6% of FOLFOXIRI cycles. In four patients, LOHP was interrupted because of grade 3 neurotoxicity (n ϭ 3) or allergic reaction (n ϭ 1).
Objective Tumor Response
According to an intention-to-treat analysis, all patients were considered assessable for response ( Table 4 ). The RR assessed by investigators was 66% for FOLFOXIRI and 41% for FOLFIRI (P ϭ .0002). The externally reviewed RR was also significantly higher for FOLFOXIRI compared with FOLFIRI (60% v 34%; P Ͻ .0001). Moreover, the rate of progression was significantly lower for patients treated with FOLFOXIRI (11% v 24%; P ϭ .02). In the multivariate analysis, only treatment with FOLFOXIRI was an independent predictive factor for response (hazard ratio [HR], 2.8; 95% CI, 1.7 to 4.8; P Ͻ .001).
Secondary Surgery on Metastases
The superior tumor shrinkage achieved with FOLFOXIRI allowed an increased rate of postchemotherapy radical surgery of metastases. In particular, 18 patients (15%) underwent to radical (R0) surgery of metastases in the FOLFOXIRI arm compared with seven patients (6%) in the FOLFIRI arm (P ϭ .033). Considering only patients with metastases confined to the liver, the rate of secondary R0 surgery of metastases was 36% for FOLFOXIRI compared with 12% for FOLFIRI (P ϭ .017). In the multivariate analysis, only treatment with FOLFOXIRI was an independent predictive factor for achieving an R0 resection (HR, 3.1; 95% CI, 1.2 to 7.9; P ϭ .018).
PFS and Second-Line Treatment
The improved activity of FOLFOXIRI resulted in an increased PFS; in particular, 104 patients in the experimental arm (FOLFOXIRI) versus 112 patients in the reference arm (FOLFIRI) have progressed, and the median PFS is 9.8 months versus 6.9 months (P ϭ .0006) with an HR for progression of 0.63 (95% CI, 0.47 to 0.81; Fig 2) . In addition, the rate of early progression (patients who progressed within 6 months from the treatment onset) was significantly lower in the FOLFOXIRI arm (18% v 45%; P Ͻ .0001). The Cox's multivariate analysis demonstrates that independent prognostic factors for reduction of the progression risk were: treatment arm (HR, 0.60; 95% CI, 0.46 to 0.79; P Ͻ .001), male sex (HR, 0.68; 95% CI, 0.51 to 0.91; P ϭ .01), and leukocyte count less than 8,000/mm 3 (HR, 0.60; 95% CI, 0.45 to 0.81; P ϭ .003). The rate of patients who received a second-line treatment was 73% for FOLFIRI and 76% for FOLFOXIRI. In particular, the regimens administered as second-line treatment (FOLFIRI v FOLFOXIRI) were FU/LV and LOHP (FOLFOX; 67% v 12%), FOLFIRI (4% v 22%), FOLFOXIRI (0% v 14%), mitomycin (0% v 14%), cetuximab (1% v 2%), and other chemotherapy (1% v 14%).
OS
After a median follow-up of 18.4 months, 65 patients in the experimental arm and 81 in the reference arm have died, and the median OS is significantly longer for FOLFOXIRI (22.6 v 16.7 months; P ϭ .032), corresponding to an HR for death of 0.70 (95% CI, 0.50 to 0.96; Fig 2) . The Cox's multivariate analysis demonstrates that the only independent prognostic factors for reduction of the death risk was liver involvement less than 25% (HR, 0.57; 95% CI, 0.39 to 0.84; P ϭ .005). Treatment with FOLFOXIRI was significantly predictive of 0  45  37  Grade 2  0  0  21  17  Grade 3  0  0  3  2  Grade 4  0  0  0  0  Astenia  NS  Grade 1  29  24  27  22  Grade 2  12  10  19  16  Grade 3  4  3  7  6  Grade 4  0  0  0  0  Thrombocytopenia  NS  Grade 1  5  4  22  18  Grade 2  3  2  7  6  Grade 3  1  1  2  2  Grade 4  0  0  0  0  Anemia  NS  Grade 1  50  41  53  43  Grade 2  11  9  23  19  Grade 3  1  1  4  3  Grade 4  0  0  0  0  Neutropenia  .0006  Grade 1  22  18  16  13  Grade 2  16  13  24  20  Grade 3  21  17  40  33  Grade 4  13  11  21  17  Febrile neutropenia  4 prolonged survival in the univariate analysis (P ϭ .032), but in the multivariate analysis, it was borderline significant (P ϭ .054).
Quality of Life
Eighty-nine patients (36% in the FOLFIRI arm and 37% in the FOLFOXIRI arm) were assessable for quality of life. Although the number of patients from whom quality-of-life questionnaires were obtained was probably too low to make clear conclusions, there were no significant differences between the two arms.
DISCUSSION
During recent years, the treatment of metastatic colorectal cancer has achieved considerable progress, mainly improvements in the efficacy of chemotherapy, for increased use of surgery on metastases, 17 and, more recently, the use of targeted agents. 18, 19 Data have suggested that exposure to all the three main active cytotoxic agents obtains the best outcome in unresectable patients, 9 but that only 50% to 80% of patients can be exposed to all three drugs in a sequential strategy with doublets. Furthermore, there is consistent evidence that by increasing the activity of chemotherapy, a greater proportion of patients can undergo a secondary surgery on metastases, and that this can allow long-term survival in a fraction of them.
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On the basis of these data, several groups have developed threedrug combinations including FU, CPT-11 and LOHP. [20] [21] [22] [23] [24] [25] In the present trial, we selected the schedule we had previously developed 15 because it was particularly convenient, well tolerated, and active compared with other three-drug combinations. We used a biweekly schedule, and we omitted the administration of FU by intravenous bolus to deliver elevated dose intensities of CPT-11, LOHP, and infusional FU.
Results obtained in the FOLFIRI arm are in line with those reported in most other randomized studies. 2, 8, [26] [27] [28] [29] With regard to FOLFOXIRI, results demonstrate that toxicities are moderately increased, mainly neurotoxicity and uncomplicated neutropenia, but this combination remains feasible and well tolerated. FOLFOXIRI clearly increased RR, which is among the highest ever reported in any randomized study of metastatic colorectal cancer. This improved activity allowed a significant increase in the rate of radical secondary surgery of metastases, and the rate of R0 patients achieved with FOLFOXIRI was particularly impressive in patients with liver metastases only (12% v 36%; P ϭ .017). The baseline unresectability of metastases was a key inclusion criterion of the trial, and centers were strongly encouraged to exclude patients with resectable metastases. However, this is was a multicenter trial, and the evaluation of resectability was not centralized, but was performed independently by the multidisciplinary team of each center. In particular, the resection rate observed with FOLFIRI was comparable to that reported in the literature; hence, it is unlikely that the improvement obtained with FOLFOXIRI resulted from different patient selection. Treatment with FOLFOXIRI was the only significant independent predictive factor for obtaining an objective response and an R0 resection. Furthermore, FOLFOXIRI significantly increased PFS by approximately 3 months, Log-rank P = .032 and it halved the risk of early progression. Finally, survival, with the limits that this was not a primary end point and that the number of patients is relatively low, was significantly improved.
These results support the hypothesis that this three-drug upfront exposure strategy is more active and probably more effective than the initial use of a doublet compared with FOLFIRI. No conclusion can be drawn with regard to the comparison with FOLFOX. However, although FOLFOX has more data with regard to the capacity to induce resectability in previously unresectable patients, similar results have been reported with FOLFIRI as well.
12 Furthermore, comparisons of FOLFOX with FOLFIRI in randomized studies have reported equivalent activity and efficacy. 8, 26 The Hellenic Oncology Research Group (HORG) reported the results of a study comparing FOLFIRI to a combination of FU, CPT-11, and LOHP. This study, although indicating some improvements for the triplet combination in terms of RR, surgical R0 resections, PFS, and OS, failed to demonstrate statistically significant benefits in favor of the triplet. 29 There are two substantial differences between the HORG study and the present study. First, in the schedule used by HORG, the FU bolus was maintained, and this required the use of a dose of LOHP and CPT-11 significantly lower than used in our study (65 v 85 mg/m 2 for LOHP and 150 v 165 mg/m 2 for CPT-11). Despite this, diarrhea was substantial (grade 3 to 4, 27.7%) and more frequent than with our combination. The second relevant difference is the study population, which was older and with a poorer performance status. In fact, in the HORG study, patients older than 75 years or between 71 and 75 but with an ECOG performance status of 1 or higher were not excluded; median age was also greater in the HORG study (66 v 62 years). In addition, only 36% of patients in the HORG study had an ECOG performance of 0 (61% in our study), and more patients had an ECOG performance status of 2 (11% v 2%). Indeed, Souglakos et al 29 report a significantly higher incidence of toxicity in older patients and those with a performance status of 2.
In conclusion, FOLFOXIRI represents the first studied combination demonstrated to be superior to an infusional FU-containing doublet compared with FOLFIRI, and this improvement in efficacy, coupled with a manageable toxicity profile, supports the use of FOLFOXIRI as a first-line option of care for selected patients with metastatic colorectal cancer. In particular, patients appropriate for FOLFOXIRI should have characteristics similar to those included in our study; therefore, patients aged more than 75 years or 71 to 75 years but with an ECOG performance status of at least 1, or with expected increased risk of toxicity (performance status of 2), should not receive this triplet. We believe that the use of FOLFOXIRI should be of particular interest in a neoadjuvant strategy in initially unresectable patients and perhaps, also, in patients with few chances to achieve a three-drug exposure in a sequential strategy. Future developments should evaluate the integration of FOLFOXIRI with targeted agents.
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